Butyrate Therapy for Poorly Differentiated Breast Cancer
Abstract
This project aims to devise a strategy for maintaining butyric acidemia in mice over a 24 hour period of time, so as to achieve a nearly complete inhibition of histone deacetylase activity. The basic approach is to use butyryiglycerides as a prodrug to butyrate and MCPA as an inhibitor of butyrate metabolism (MCPA). We monitor for both vital signs and blood chemistries to assure survival during the prolonged metabolic acidosis. Our hypothesis is that such a scheme will allow maintenance of butyrate blood levels between 1 and 5 mM, and that the mice will develop hyperacetylation of chromatin core histones sufficient to cause extensive cytolysis in xenografted tumors with known sensitivity to butyrate-induced apoptosis.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1999
- Accession Number
- ADA382836
Entities
People
- John Mcbain
Organizations
- Dartmouth College